SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike (NKE) is trending lower after its latest earnings report, despite surpassing revenue and EPS estimates, driven by concerns over declining gross margins, weak direct-to-consumer sales, and ongoing softness in China. The community is sharply divided, with many debating if this presents a strong buying opportunity for the iconic brand or signals continued challenges amid intense competition and questions about product innovation and leadership.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media (DJT) is actively trending following news of its merger with TAE Technologies, positioning the company as an early publicly traded entrant in the fusion energy sector. This dramatic pivot from social media to "fusion + AI power" is driving intense community discussion and high volatility. While many anticipate significant upside and a short squeeze, others remain skeptical, viewing it as a speculative play with concerns over profitability and dilution.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is trending due to a recent analyst upgrade with a $20 price target and strong market anticipation for NASA's multi-billion dollar Lunar Terrain Vehicle (LTV) contract award. The community believes LUNR is a leading contender for this critical lunar mission, fueled by a renewed government focus on space exploration and broader investor enthusiasm for the sector, which many expect could trigger a significant short squeeze.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies (BMNR) is trending amid discussions surrounding the Bank of Japan's monetary policy and its potential effects on the crypto market, especially Ethereum. A major community talking point involves a proposed share authorization, sparking intense debate between those fearing significant dilution and others seeing it as a strategic move to increase Ethereum holdings. This, coupled with recent market volatility and scrutiny over prominent analyst predictions, highlights significant uncertainty and strong opinions on BMNR's future as an Ethereum-linked asset.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber Inc. (WYFI) is trending following the announcement of a substantial 10-year, $865 million colocation agreement with Nscale for its NC-1 data center campus, securing 40 MW for AI infrastructure. The community views this as a significant catalyst, improving revenue visibility and fueling expectations for a potential multi-day rally and short squeeze given the company's low free float. This strategic deal reinforces WhiteFiber's role in the booming AI data center sector, which continues to see high demand for specialized capacity.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is a major topic of conversation as markets react to the Bank of Japan's interest rate decision, with community sentiment sharply divided on whether the move is already priced in or will trigger an unwind of the yen carry trade. This critical event, coupled with recent scrutinized inflation data and a significant options expiry, is fueling intense debate about broader market direction and volatility.

Vanguard Malvern Funds - Vanguard Short-Term Inflation-Protected Securities Index Fund

Vanguard Short-Term Inflation-Protected Securities ETF

VTIP is trending as investors keenly evaluate its role as a short-term inflation-protected investment amidst persistent inflation concerns and broader market volatility. Community discussions center on its perceived value as a safe-haven asset for stable income, with many viewing it as potentially undervalued despite recent price movements, while also debating its effectiveness compared to other inflation hedges.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as the market reacts to the Bank of Japan's rate hike decision, sparking widespread debate among investors on its impact, particularly concerning the yen carry trade. This event, coupled with mixed community reactions to recent inflation data and ongoing concerns about an AI bubble, is driving high volatility and varied market predictions.

KB Home engages in selling and building a variety of new homes. It builds various types of homes, including attached and detached single-family homes, townhomes, and condominiums. The firm operates through the following segments: West Coast, Southwest, Central, and Southeast. It offer homes in development communities, at urban in-fill locations and as part of mixed-use projects. The company was founded in 1957 and is headquartered in Los Angeles, CA.

KB Home

KB Home is trending as investors weigh its recent earnings and forward guidance against a volatile housing market. Community discussion is split, with some anticipating a sector revival driven by potential interest rate moderation and "big money" interest, while others remain cautious due to ongoing affordability challenges and concerns about slowing demand. The company's performance and outlook are central to a broader debate on the homebuilding sector's resilience in the current economic climate.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is a focal point for investors following preliminary FLAMINGO-01 trial data, which reported an estimated 80% reduction in breast cancer recurrence rates from its open-label arm. This positive update, combined with an extremely high cost-to-borrow rate and a tightly held low float, is fueling intense short squeeze speculation and buyout discussions among the community. However, some investors are closely scrutinizing the preliminary nature of the data due to the absence of a direct placebo comparator.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ETF Fundamental Report for IWM

Below is Validea's ETF fundamental report for iShares Russell 2000 ETF (IWM). The report looks at IWM's exposure to the major investing factors including value, quality, momentum and low volatility...

5 Momentum ETFs With More Room to Run in 2026

AI strength, solid earnings, and upbeat 2026 forecasts fuel momentum plays. These five ETFs -- GDXJ, SLV, KBE, MDYV & IWM -- may still have room to run.

Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank

Adding to the unusually strong performance of the Russell 2000 this year, these top performers may certainly serve as stocks to add to your watchlist

Zacks Investment Ideas feature highlights: Carvana, Lennar, Bank of America, Newmont Mining and the Russell 2000 Index ETF

A widely expected Fed rate cut puts Powell's tone in focus as investors watch how Carvana and other rate-sensitive names react.

December FOMC Preview: Rate Cut Priced in but Tone is Everything

On Wednesday, the Federal Reserve will take center stage. With a rate cut widely expected, the real story will be expectations for 2026 and how the Fed balances softening employment data with ongoing economic strength.

<ul class="summary-bullets"><li>The S&amp;P 500 is only trading within a 100-point range from its all-time highs.</li><li>Retail traders have bearish retail positioning on SPY and QQQ amid skepticism over Nvidia’s chip-export approval to China.</li><li>Siegel expects a flat December performance but sees potential for healthy consolidation and rotation into smaller, rate-sensitive stocks.</li></ul>U.S. stock futures traded narrowly mixed early Tuesday, underscoring the indecision among traders as they await the Federal Reserve’s final rate decision for the year. Risk sentiment could also take a beating from President Donald Trump’s renewed tariff salvo fired at North American neighbors, Mexico and Canada, as well as India.Writing on Truth Social, Trump&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/115686410399815717">berated</a> Mexico for violating the Water Treaty and issued an ultimatum: if Mexico does not release the agreed-upon water quota, a 5% tariff will be imposed. Separately, while speaking at a White House event, the president said he was mulling fresh tariffs on agricultural products such as Indian rice and Canadian fertilizer, Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-12-08/trump-eyes-tariffs-over-cheap-canadian-fertilizer-indian-rice">reported.</a>Traders may also sift through a couple of economic data points and some key earnings reports as they plot their next moves.WisdomTree Senior Economist Jeremy Siegel calls for a relatively flat performance in December as the markets digest the Fed’s message and wait for clarity on tariffs and policy heading into 2026. In his weekly commentary, the economist and strategist said, “The one seasonal I do give more weight to is the short window between Christmas and New Year’s, the so-called Santa Claus rally.”The strategist said the consolidation he predicts would be healthy "if it comes with a subtle rotation — away from over-owned megacaps and toward smaller, rate-sensitive names that benefit most from the first leg of easing.”<h2 class="st-heading-2">How Futures Are Trading</h2>As of 2:40 a.m. ET on Tuesday, the Nasdaq 100 futures, S&amp;P 500, and Dow futures were marginally higher, while the Russell 2000 futures traded down 0.08%.On Stocktwits, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, remained ‘bearish’ as of early Tuesday. The message volume on the SPY and QQQ ETF streams remained at ‘normal’ and ‘high’ levels, respectively.Most observers did not view the Trump administration’s decision to allow the export of Nvidia’s H200 chips to China favorably, as they doubted China's uptake.<stembedurl>https://stocktwits.com/newsman07336/message/638555952</stembedurl>Another user stated that a Santa Claus rally, which gives the market a year-end lift, is unlikely this year.<stembedurl>https://stocktwits.com/8Inevitableoutcome/message/638552484</stembedurl><h2 class="st-heading-2">How Markets Fared Monday</h2>Stocks were in a “wait-and-watch” mode on Monday amid uncertainty surrounding the Fed decision, due Wednesday. All but the IT sector closed in the red, with communication services, consumer discretionary, material, healthcare, and utility stocks ending markedly lower. In the process, the S&amp;P 500 Index moved away from its all-time high of 6,920.34 before settling at 6,846.51.The QQQ, SPY, and&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust (DIA)</a> fell 0.19%, 0.32% and 0.39%, respectively, while the&nbsp;<a href="https://stocktwits.com/symbol/IWM">iShares Russell 2000 ETF (IWM)</a> closed marginally higher.<h2 class="st-heading-2">Key Catalysts To Watch Out For</h2>The National Federation of Independent Business (NFIB) is scheduled to release its optimism index for November at 6 a.m. ET. The index, which measures optimism among small businesses, is expected to remain unchanged at 98.2.The Bureau of Labor Statistics is set to release the results of the Job Openings and Labor Turnover (JOLTS) survey for October at 10 a.m. ET. The reading will be closely watched, as the government suspended the release of the September report due to the shutdown.Notable names reporting earnings on Tuesday are AutoZone (AZO), G-III Apparel (GIII), Sailpoint (SAIL), AeroVironment (AVAV), Casey’s General (CASY), Cracker Barrel (CBRL), and GameStop (GME).&nbsp;<h2 class="st-heading-2">How Other Markets Fared</h2>The Asian markets fell across the board as the Fed decision loomed, while Japanese stocks closed modestly higher, supported by the yen's weakness. In a major central bank decision from the region, the Reserve Bank of Australia announced a pause, in line with expectations, and hinted that further easing is unlikely.The greenback was weaker against most major currencies, except the yen. The 10-year U.S. Treasury note yield was little changed early Tuesday after rising 3.3 points to 4.172% in the previous session. Among commodities, crude oil futures fell modestly, with the WTI crude now trading below $59 level, and gold futures also eased.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/what-a-post-powell-fed-may-look-like-under-trump-favorite-kevin-hassett/cLIYqZPREm7">What A Post-Powell Federal Reserve May Look Like Under Trump Favorite Kevin Hassett</a>

Traders work on the floor of the New York Stock Exchange (NYSE) on October 01, 2025, in New York City.  

Nasdaq, S&P 500 Futures Freeze As Fresh Trump Tariff Threats On Mexico, India Collide With Fed Jitters — Strategist Warns Santa Rally Looks Unlikely

The muted action reflects a broader sense of indecision across markets, with traders weighing the central bank’s interest-rate path against the latest geopolitical and trade uncertainties.

Equity

The muted action reflects a broader sense of indecision across markets, with traders weighing the central bank’s interest-rate path against the latest geopolitical and trade uncertainties.


Why High-Income Seekers Are Turning to Autocallable ETFs

We explain how Autocallable ETFs work and who they are for.


<ul class="summary-bullets"><li>H.C. Wainwright conservatively expects approval by the middle of 2026 and sees the shares trading well into the year-end.</li><li>Capricor’s bumper rally on Wednesday helped the stock turn green for the year.</li><li>Retail sees the stock as a long-term winner following the Phase 3 results.</li></ul>Two decades after its modest beginnings and more than a decade after becoming a public company, San Diego, California-based Capricor Therapeutics made another stride toward becoming a commercial-stage company. After a failed first try, the small-cap biotech is hoping to push its experimental cell-therapy for a rare genetic muscular disorder past the finish line without any hiccups.Wall Street analysts and the investment community received the recently released late-stage trial data for the treatment candidate well. While sell-side analysts were generous with their price target hikes, signaling their excitement toward the data, investors sent the stock up by over 530% at one point in Wednesday’s session. The initial euphoria faded slightly, but didn’t die out, as<a href="https://stocktwits.com/symbol/CAPR">&nbsp;Capricor’s stock</a> had enough verve to finish the day up 371% at $29.96,&nbsp;ending at an eight-year high and marking its best day ever.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_2_28_48_AM_png_599beb080a.webp" alt="Screenshot 2025-12-04 at 2.28.48 AM.png">Source: Koyfin<h2 class="st-heading-2">What Fueled CAPR’s Stratospheric Rally</h2>Wednesday, before the market opened, Capricor reported positive topline results from the Phase 3 study, dubbed HOPE-3, evaluating its Duchenne Muscular Dystrophy (DMD) cell therapy candidate, Deramiocel.-The primary endpoint, measured as the performance of upper limb (PUL), was met — showing statistically and clinically meaningful treatment effects in 54% of the patients.-The key secondary endpoint of “Left Ventricular Ejection Fraction (LVEF),” a measure of heart health, was also met.&nbsp;Thus, Deramiocel was shown to produce significant skeletal and cardiac benefits, supporting its credentials as a potential “first-in-class therapy” for Duchenne cardiomyopathy, the leading cause of mortality in DMD. The trial also gave the cell therapy a clean chit for its safety and tolerability.Capricor said it would submit the detailed results from the HOPE-3 study at a future scientific meeting and for publication in a peer-reviewed journal.Earlier in July, the FDA shot down Capricor’s initial application for Deramiocel, issuing a complete response letter (CRL) — a notice that an application cannot be approved in its current form. The agency expressed wariness about the company's efficacy data at the time and sought additional data. Industry experts saw it as a signal that the new leadership at the FDA could be veering toward a cautious approach.&nbsp;&nbsp;CEO Linda Marbán said the study results, in addition to the evidence from the HOPE-2 and HOPE-2 OLE studies, would address the clinical issues in the CRL and support regulatory approval.DMD is caused by a mutation in the DMD gene that prevents the body from producing the protein dystrophin. A lack of dystrophin hits muscle fibres, leading to muscle damage and loss.&nbsp;<h2 class="st-heading-2">What’s At Stake For Capricor</h2>According to Grand View Research, the DMD drugs<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.grandviewresearch.com/industry-analysis/duchenne-muscular-dystrophy-dmd-drugs-market">&nbsp;market</a> is expected to grow at a compounded annual growth rate (CAGR) of 16.8% from 2024, reaching $9.91 billion in 2030. North America’s revenue share was at 45% in 2023. Global Data, meanwhile, has a more muted forecast, predicting a $5.2 billion market opportunity in 2033.&nbsp;<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_3_25_08_AM_png_f4173223fa.webp" alt="Screenshot 2025-12-04 at 3.25.08 AM.png">Source: Grandview ResearchThe DMD market is currently led by Sarepta, which has a gene-replacement therapy called Eteplirsen. Elevidys, a one-time single-dose gene transfer therapy, was approved in June 2023, and its label was expanded a year later to include patients ages four and older. The gene therapy generated $131.5 million in revenue for Sarepta in the third quarter.Capricor’s Deramiocel differs from Elevidys in that it is a cell therapy that administers the patient's cardiosphere-derived cells, which secrete exosomes. The latter uses a manufactured gene for delivering the micro-dysrophin gene.Sarepta also has three FDA-approved exon-skipping therapies, Exondys 51, Amondys 45 and Vyondys 53, and it is also currently working on RNA therapies.<h2 class="st-heading-2">Big Price Target Bumps</h2>Following the data, H.C. Wainwright upped the price target for Capricor's stock to $60 from $24 and kept a 'Buy' rating, the Fly reported. The firm called the data a "decisive" win. With 78% of participants having underlying cardiomyopathy, the trial results addressed FDA concerns about sample size, the firm said. It conservatively expects approval by the middle of 2026 and sees the shares trading well into the year-end.Alliance Global called the data "unequivocally and wholly positive" and removed the speculative tag from the stock. The firm hiked its price target for the stock to $48 from $16.<h2 class="st-heading-2">Retail Convinced Of Capricor Opportunity</h2>On Stocktwits, retail investors held an 'extremely bullish' stance on Capricor stock as of early Thursday. The message volume on the stream was 'extremely high as well.A majority of retail traders are sold on Capricor's long-term potential. An ongoing Stocktwits poll asking users "What's your move on $CAPR after this Phase 3 win?" found that 53% of respondents said "This is legit — CAPR becomes a long-term winner," while 18% remained on the sidelines, waiting for approval to come through. About 29% shrugged off the rally as an "overreaction."<a href="https://stocktwits.com/StocktwitsPolls/message/638043423"><img src="https://news.stocktwits-cdn.com/CAPR_Stocktwits_poll_png_bc7624531b.webp" alt="CAPR Stocktwits poll.png"></a>CAPR stock has&nbsp;soared about 117% this year, as Wednesday's bumper rally helped it recoup all its losses to that point and turn green for the year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/core-weave-vs-nebius-ai-infra-s-breakout-duo-backed-by-nvidia-is-outrunning-big-tech/cLIXYiKRE12">&nbsp;</a><a href="https://stocktwits.com/news-articles/markets/equity/whispers-of-an-apple-deal-rebooted-intel-s-year/cLIXAvERE1L">Whispers Of An Apple Deal Rebooted Intel’s Year — Now The Market’s Asking Whether The Old Chip Giant Can Rise Again</a>

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Capricor’s Red-Hot Rally Has Wall Street And Retail Hooked — And Fresh DMD Data Could Keep Fueling The Fire

 DMD patients may soon gain access to a therapy that not only targets muscle decline but also tackles heart complications — the leading cause of death in this rare genetic disorder.

ETFs to Benefit From Rate Cut Bets and Upbeat Forecasts

ETFs to watch as Wall Street turns upbeat, with bullish forecasts putting the S&P 500 on track for 8,000 by 2026.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Current Price	$248.71
Prev Close	$247.24
Open	$250.18
Dividend Yield	N/A
50-Day Moving Average	$245.20
Beta	N/A
Avg. Volume	48.49M
PE Ratio	N/A

52-Week High	$258.20
52-Week Low	$171.73
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWM News

IWMiShares Russell 2000 ETF